
Foghorn Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from H.C. Wainwright reiterated a Buy rating on the stock and has a
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| FHTX | Foghorn Therapeutics | 1.78 | -3.00 | -62.79% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.78 | -62.79% |

Foghorn Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from H.C. Wainwright reiterated a Buy rating on the stock and has a

Reports Q3 revenue $83.54M, consensus $7.1M. Collaboration revenue was $83.5M for the three months ended September 30, compared to $8.2M for the three months ended September 30, 2025. The $75.4M

The latest announcement is out from Foghorn Therapeutics ( ($FHTX) ). On November 9, 2026, Foghorn Therapeutics provided its third-quarter corporate and financial update, reporting collaboration revenue of $83.5 million

Foghorn Therapeutics, Inc. (FHTX) is scheduled to report 3rd quarter earnings on 11/10/2026. Regarding Q3 estimates, Wall Street analysts expect Foghorn Therapeutics, Inc. to post earnings of -$0.24 per share.

Evercore ISI downgraded Foghorn Therapeutics (FHTX) to In Line from Outperform with a price target of $3, down from $14. The firm cites the FHD-909 failure for the downgrade. Foghorn’s

Wedbush downgraded Foghorn Therapeutics (FHTX) to Neutral from Outperform with a price target of $2, down from $10, after the company and Eli Lilly (LLY) elected not to advance FHD-909

Wedbush analyst Robert Driscoll downgraded Foghorn Therapeutics (FHTX) to Neutral from Outperform with a price target of $2, down from $10. Published first on TheFly – the ultimate source for

Guggenheim lowered the firm’s price target on Foghorn Therapeutics (FHTX) to $5 from $12 and keeps a Buy rating on the shares after the company announced that they and partner

H.C. Wainwright lowered the firm’s price target on Foghorn Therapeutics (FHTX) to $5 from $13 and keeps a Buy rating on the shares after the company announced the discontinuation of

TD Cowen downgraded Foghorn Therapeutics (FHTX) to Hold from Buy without a price target The company and Eli Lilly’s decision not to advance FHD-909 into dose expansion, which in turn
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 11, 2027TBA | $107.33M | $-0.27 | $1.56M | 0.18 | 25.21 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.